-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Neutral on Lumos Pharma, Maintains $4.25 Price Target

Benzinga·11/08/2024 16:22:30
Listen to the news
HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Neutral and maintains $4.25 price target.